INTRODUCTION

Atherosclerosis, as one of the most serious complication of diabetes, is often found at the early phase of diabetes when vascular endothelial cell injury takes place. Compared with nondiabetic subjects, type 2 diabetes mellitus (T2DM) could favor a high risk of macrovascular disease. Adipokines are cytokines (cell-signaling proteins) secreted by adipose tissue, including adiponectin, leptin, interleukin-6, and chemerin. Several studies have indicated that adipokine imbalance can lead to atherosclerosis and this is critical in...
the development of diabetes.\textsuperscript{4,5} Obese adipose tissue secretes high amounts of chemerin and low levels of adiponectin, which leads to a pathogenic and pro-inflammatory environment for the development of atherosclerosis and diabetes.\textsuperscript{3,4} Previous studies have suggested that serum adipokine levels may be helpful for the early diagnosis of atherosclerosis.\textsuperscript{1,6} Pulse wave velocity (PWV), including carotid-femoral PWV and brachial-ankle PWV (ba-PWV), is the gold standard to assess arterial stiffness, as well as in identification of early stage of atherosclerosis and cardiovascular events, but its clinical application is limited due to the operation's complexity.\textsuperscript{7,8} Still, whether the plasma levels of chemerin and adiponectin could reflect the degree of atherosclerosis in T2DM is still unknown.\textsuperscript{9-11}

In this study, we divided all patients with T2DM into three groups according to their ba-PWV values. The levels of adiponectin and chemerin together with other clinical parameters were measured and compared among all groups. Overall, our findings indicated that the plasma levels of adiponectin and chemerin correlated with the development of vascular stiffness, which may lead to atherosclerosis in T2DM.

\section{METHODS AND SUBJECTS}

\subsection{Patients and samples}

This cross-sectional study included 129 subjects (aged over 65 years), including nine healthy older adults and 120 older patients with T2DM who had undergone medical treatment from June 1, 2015 to December 1, 2015 in the general department of the Mawangdui Campus of Hunan Province People's Hospital. Diabetes had been diagnosed according to the 1999 World Health Organization Diabetes Diagnosis Standard. We excluded patients with acute or chronic infectious disease, cerebrovascular disease, malignant tumor, severe liver and/or kidney disease, acute myocardial infarction, immune system diseases, surgery history or trauma within the previous half-year, and administration of rosiglitazone medicine. The present study was approved by the Research Ethics Committee of Hunan Normal University. Before enrollment, written informed consent was acquired from each individual. Some basic clinical characteristics of all T2DM patients are shown in Table 1.

\subsection{Data collection and biochemical measurements}

After enrollment, a serial medical examination was carried out, including age, history of T2DM, blood pressure (diastolic [DBP] and systolic [SBP]), height, weight, waist circumference, and hip circumference. Body mass index (BMI) was calculated by weight/height\(^2\) (kg/m\(^2\)). We collected venous blood from all study subjects after 10 hours' fasting. A fully automatic biochemical analyzer (AU-640) was utilized to examine the liver function markers, total cholesterol, triglyceride, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), albumin, glycosylated hemoglobin, C-reactive protein (CRP), renal function markers, and fasting glucose. Electro-chemiluminescence assays were used to detect the fasting insulin and C peptide levels. Meanwhile, the plasma was collected from 3-mL blood samples (centrifuged for 5 minutes at a speed of 1917 g) and stored at \(-80^\circ\) for further analysis. Enzyme-linked immunosorbent assay was used to examine adiponectin (No. ABIN364986, ACRIS) and chemerin (SEA945Hu, Cloud-Clone) levels in plasma. Samples were first incubated in microtitration wells for 60 minutes, then washed and incubated with biotin-labeled polyclonal anti-human chemerin or adiponectin antibody at 37°C for 90 minutes. After another washing, streptavidin-horseradish peroxidase conjugate was added and samples were incubated at 37°C for 30 minutes. The reaction was stopped with acidic solution (H2SO4). An enzyme standard instrument was used to detect the optical density (OD) value at 450 nm. Finally, we plotted a standard curve to calculate the chemerin and adiponectin concentrations of each sample. Meanwhile, the ba-PWV, bone mineral density T value (DPX-Bravo), and ankle-brachial index (ABI) were examined as in previous studies.\textsuperscript{10,12}

\subsection{Statistical analysis}

All analyses were done with IBM SPSS Statistics Version 22.0. The data according to normal distribution are shown as mean \(\pm\) SD, otherwise logarithmic transformation was carried out. Before further analysis, we first carried out an F test and a normality test. The Student’s t test was utilized to assess the difference between different groups. Correlation analysis between two factors was analyzed with Pearson's test. \(P < .05\) was considered as a statistically significant difference. Multiple linear stepwise regression analysis was applied to verify principal influence factors.

\section{RESULTS}

\subsection{Evaluation of the correlation of ba-PWV and several clinical parameters in T2DM patients}

Several clinical parameters were collected and measured from all the enrolled patients as well as healthy controls (HCs). The insulin, insulin resistance index, and ba-PWV levels were significantly higher in T2DM patients than in HCs (\(P < .05\)), which is consistent with our diagnosis in the inpatient clinic. The 120 T2DM subjects were separated into three groups according to the ba-PWV level: the high-, moderate-, or low-ba-PWV groups. The clinical parameters were compared among the different groups. The high-ba-PWV group had elevated levels for SBP, BMI, glycosylated hemoglobin, CRP, brain natriuretic peptide (BNP), LDL-C, and fasting glucose insulin, while its levels for albumin, HDL-C, bone mineral density T value score, and ABI were significantly lower than those in the moderate-ba-PWV group (\(P < .05\); Table 2). Compared with the low-ba-PWV group, the high-ba-PWV group showed higher levels for T2DM history, DBP, waist circumference, and insulin (\(P < .05\); Table 2). Furthermore,
lower levels for SBP, BMI, waist circumference, BNP, and LDL-C were observed in the low-ba-PWV group, along with higher levels for HDL-C, bone mineral density T value score, and ABI compared with the moderate-ba-PWV group (P < .05; Table 2). Interestingly, ABI, which protects generalized atherosclerosis at high levels, was negatively associated with ba-PWV levels, and their combination has been suggested for better diagnosis of atherosclerosis. There were no differences in age, aspartate aminotransferase, hip circumference, blood urea nitrogen, creatinine, uric acid triglycerides, total cholesterol, or C peptide among these groups (P < .05).

### 3.2 Evaluation of the links between chemerin and adiponectin levels and ba-PWV in T2DM patients

First, power analysis was carried out according to Cohen's d by using G'Power software, and support our experiment design with the sample size analyzed in each group in this study (Figure 1). We compared the chemerin and adiponectin levels between HC older adults (n = 9) and T2DM patients (n = 120). T2DM patients had higher levels of chemerin than HC older adults (T2DM vs HC, 136.39 ± 20.98 vs 56.99 ± 10.07 ng/mL, P < .05) and lower levels

### TABLE 1 Clinical parameters of all T2DM patients and healthy controls

| Parameter                  | N = 120, Male/Female = 70/50 | Healthy controls |
|----------------------------|-------------------------------|------------------|
| Age (y)                    | 65.00 – 97.00                | 83.83 ± 6.50     |
| History of T2DM (y)        | 10.00 – 32.00                | 21.40 ± 4.94     |
| SBP (mm Hg)                | 106.00 – 170.00              | 140.41 ± 13.11   |
| DBP (mm Hg)                | 55.00 – 98.00                | 76.67 ± 9.19     |
| BMI (kg/m²)                | 18.49 – 34.55                | 23.97 ± 3.12     |
| Waist circumference (cm)   | 75.00 – 115.00               | 97.12 ± 8.07     |
| Hip circumference (cm)     | 77.00 – 120.00               | 100.71 ± 8.65    |
| Waist-to-hip ratio         | 0.81 – 1.14                  | 0.97 ± 0.07      |
| GPT (U/L)                  | 5.00 – 51.00                 | 20.48 ± 8.39     |
| AST (U/L)                  | 10.00 – 44.00                | 23.02 ± 7.56     |
| BUN (mmol/L)               | 2.50 – 25.00                 | 6.23 ± 2.41      |
| Serum creatinine (µmol/L)  | 37.00 – 229.00               | 85.44 ± 25.43    |
| Triglycerine (µmol/L)      | 204.00 – 455.00              | 310.28 ± 57.62   |
| GH (%)                     | 3.70 – 11.50                 | 6.03 ± 1.27      |
| CRP (mg/L)                 | 0.20 – 21.30                 | 3.00 ± 2.80      |
| Albumin (g/L)              | 31.00 – 49.00                | 38.19 ± 3.47     |
| BNP (pg/mL)                | 103.00 – 3100.00             | 1033.54 ± 795.13 |
| LDL-C (mmol/L)             | 0.80 – 6.10                  | 2.28 ± 0.96      |
| HDL-C (mmol/L)             | 4.50 – 1.89                  | 1.10 ± 0.30      |
| Triglyceride (mmol/L)      | 0.32 – 3.20                  | 1.43 ± 0.58      |
| Total cholesterol (mmol/L) | 1.98 – 7.70                  | 3.73 ± 0.95      |
| BMD T value                | −6.60 – 2.20                 | −1.56 ± 1.53     |
| ABI                        | 0.60 – 4.40                  | 1.01 ± 0.42      |
| C peptide (ng/mL)          | 0.18 – 4.82                  | 1.92 ± 1.02      |
| Insulin (pmol/L)           | 0.45 – 788.00                | 172.60 ± 170.86  |
| Chemerin (ng/mL)           | 90.60 – 196.92               | 136.39 ± 20.98   |
| Adiponectin (µg/mL)        | 8.16 – 44.41                 | 12.75 ± 4.56     |
| FBG (mmol/L)               | 3.90 – 14.40                 | 6.24 ± 1.94      |
| IRI                        | 0.02 – 59.92                 | 7.84 ± 10.10     |
| ba-PWV (cm/s)              | 1450.00 – 4292.00            | 2391.78 ± 509.00 |

Abbreviations: ABI, ankle-brachial index; AST, aspartate aminotransferase; ba-PWV, brachial-ankle pulse wave velocity; BMD T value, bone mineral density T value; BMI, body mass index; BNP, brain natriuretic peptide; BUN, blood urea nitrogen; CRP, C-reactive protein; DBP, diastolic blood pressure; FBG, fasting blood glucose; GH, glycosylated hemoglobin; GPT, glutamic-pyruvic transaminase; HDL-C, high-density lipoprotein cholesterol; IRI, insulin resistance index; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure; T2DM, type 2 diabetes mellitus.

*P < .05.
of adiponectin were detected in T2DM patients (T2DM vs HC, 12.75 ± 4.56 vs 20.64 ± 2.52 µg/mL, *P* < .05).

Next, the chemerin and adiponectin levels among these three groups were compared. Both the high- and moderate-ba-PWV groups showed higher levels of chemerin than the low-ba-PWV group (Figure 2). Interestingly, inverted results were observed for adiponectin production in the low-ba-PWV group (Figure 3). Furthermore, the correlation analysis showed that chemerin and adiponectin levels were
significantly related to ba-PWV levels (chemerin, \( r = 0.806, P < .001 \); adiponectin, \( r = -.554, P < .001 \); Table 3).

3.3 Identification of the early diagnostic markers for vascular stiffness in T2DM patients

To investigate the potential markers for the prediction of atherosclerosis, we analyzed the correlation between chemerin levels and these measured clinical parameters in T2DM patients. As shown in Tables 4 and 5, chemerin and adiponectin levels in plasma were significantly related to history of T2DM, SBP, DBP, BMI, waist circumference, waist-to-hip ratio, glycosylated hemoglobin, CRP, BNP, LDL-C, triglycerides, total cholesterol, insulin, fasting glucose, insulin resistance index, hip circumference, albumin, HDL-C, bone mineral density T value score, and ABI (\( P < .001 \)). Furthermore, our multiple linear regression analysis showed that chemerin and adiponectin
Abnormal adipose tissue secretes chemerin and adiponectin—pro-inflammatory and anti-inflammatory substances, which may link obesity to diabetes, atherosclerosis, and cardiovascular disease.\(^4,15,16\) In the present study, we observed higher levels of chemerin and lower levels of adiponectin in the high-ba-PWV T2DM group than in the low- and moderate-ba-PWV T2DM groups. Chemerin and adiponectin levels were significantly correlated with ba-PWV levels. Furthermore, the presence of chemerin and adiponectin was significantly associated with the levels of several clinical parameters. Overall, this study suggests that plasma levels of chemerin and adiponectin are closely related to the development of vascular stiffness, and may be useful for the diagnosis of early stage atherosclerosis.

In this study, all enrolled T2DM patients showed different degrees of atherosclerosis, which provides more evidence supporting the theory that diabetes promotes the development of atherosclerosis.\(^17\) Similar results have been observed in previous reports: The ba-PWV level is significantly correlated with several clinical parameters that are risk factors for atherosclerosis, such as glycosylated hemoglobin and CRP.\(^10\) PWV values represent a gold standard for measuring arterial stiffness, which is determined principally by age and blood pressure.\(^18\) Arterial stiffening and atherosclerosis share some common pathophysiological mechanisms, such as endothelial dysfunction and insulin resistance.\(^19\) In addition, insulin resistance has been connected to the constant arterial stiffening found in diabetic patients,\(^20,21\) while the stiffness may be further increased by endothelial dysfunction and high levels of gamma-glutamyltransferase and leptin, and by decrease in adiponectin levels involving mechanisms implicated also in preclinical atherosclerosis.\(^22-25\) Our studies in T2DM patients showed similar findings to support this theory. Nevertheless, Maedeker et al\(^26\) suggested that the increased vascular stiffness may simply be a consequence of the pathological changes during the progression of atherosclerosis, which positively reinforces the link between stiffness and atherosclerosis.

Recently, many studies have pointed out that adipose tissue is an endocrine organ, rather than just functioning as a fuel repository.\(^27,28\) Adipose tissue secretes a series of adipokines, such as leptin, tumor necrosis factor, interleukin-6, angiotensin, chemerin, insulin-like growth factor, and adiponectin, which diversifies their functions in obesity patients.\(^4,28\) Our results showed that chemerin and adiponectin levels were significantly related to a history of T2DM and to ba-PWV levels, suggesting that chemerin and adiponectin may play critical roles in the progression of T2DM and of vascular stiffness. Chemerin is one of the G-protein-coupled receptor (chemerin R23) ligands, which promote the function of mature fat cells, synthesize triglycerides, transport glucose, and inhibit lipid degradation, thus reducing blood sugar levels under normal circumstances.\(^29,30\) Chemerin can promote cholesterol intake and foam-cell formation, which causes atherosclerotic plaque formation.\(^31,32\) Furthermore, chemerin also enhances HDL-associated paraoxonase-1 activity and triggers high-grade inflammation and oxidative stress, which consequently increases the oxidized LDL level and

---

**FIGURE 2** Comparison of chemerin levels among the low, moderate, and high brachial-ankle pulse wave velocity (ba-PWV) groups in type 2 diabetes mellitus patients. Significant differences were calculated with the Student's t test.

**FIGURE 3** Comparison of adiponectin levels among the low, moderate, and high brachial-ankle pulse wave velocity (ba-PWV) groups in type 2 diabetes mellitus patients. Significant differences were calculated with the Student's t test.

**TABLE 3** Correlation between plasma chemerin or adiponectin and ba-PWV levels

| Parameter   | ba-PWV          | Correlation (r) | P value |
|-------------|-----------------|----------------|---------|
| Adiponectin |                | -.554          | <.001   |
| Chemerin    |                | .806           | <.001   |

Abbreviation: ba-PWV, brachial-ankle pulse wave velocity.
induces atherosclerosis. Consistent with other findings, our results suggest that chemerin could be considered as a marker for subclinical vascular stiffness detection in T2DM patients. Adiponectin, an adipocyte-specific secretory protein, is mainly regulated in endothelial inflammatory responses. In contrast to chemerin, adiponectin is important in transporting glucose, regulating lipid metabolism, and improving insulin sensitivity, which elicit an anti-inflammatory role in inhibiting the formation of atherosclerosis. A previous study on rhesus monkeys with type 2 diabetes showed that adiponectin levels are decreased in parallel with reduced insulin sensitivity. Our results are similar to previous findings that adiponectin level in plasma is significantly related to subclinical vascular stiffness in asymptomatic patients with type 1 diabetes mellitus. Furthermore, ABI and ba-PWV levels are crucial risk factors for cardiovascular diseases.

### Table 4: Correlation between plasma chemerin and clinical parameters

| Parameter           | Chemerin Correlation (r) | P value | Parameter           | Chemerin Correlation (r) | P value |
|---------------------|--------------------------|---------|---------------------|--------------------------|---------|
| History (y)         | .164                     | .037    | LDL-C               | .474                     | <.001   |
| SBP (mm Hg)         | .604                     | <.001   | HDL-C               | -.570                    | <.001   |
| DBP (mm Hg)         | .262                     | .004    | Triglyceride (mmol/L) | .152                    | .049    |
| BMI (kg/m²)         | .541                     | <.001   | Total cholesterol (mmol/L) | .325                    | <.001   |
| Waist circumference (cm) | .290                 | .001    | BMD T value        | -.763                    | <.001   |
| Hip circumference (cm) | -.183                 | .023    | ABI                | -.475                    | <.001   |
| Waist-to-hip ratio  | .593                     | <.001   | Insulin (µmol/L)   | .510                     | <.001   |
| GPT (U/L)           | .416                     | <.001   | FBG (mmol/L)       | .324                     | <.001   |
| CRP (mg/L)          | .343                     | <.001   | IRI                | .473                     | <.001   |
| Albumin (g/L)       | -.261                    | .002    | Adiponectin        | -.527                    | <.001   |
| BNP (pg/mL)         | .474                     | <.001   | ba-PWV             | .806                     | <.001   |

**Abbreviations:** ABI, ankle-brachial index; ba-PWV, brachial-ankle pulse wave velocity; BMD T value, bone mineral density T value; BMI, body mass index; BNP, brain natriuretic peptide; CRP, C-reactive protein; DBP, diastolic blood pressure; FBG, fasting blood glucose; GPT, glutamic-pyruvic transaminase; HDL-C, high-density lipoprotein cholesterol; IRI, insulin resistance index; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure.

### Table 5: Correlation between plasma adiponectin level and clinical parameters

| Parameter           | Adiponectin Correlation (r) | P value | Parameter           | Adiponectin Correlation (r) | P value |
|---------------------|-----------------------------|---------|---------------------|-----------------------------|---------|
| SBP (mm Hg)         | -.351                       | <.001   | HDL-C               | .420                        | <.001   |
| DBP (mm Hg)         | -.232                       | .011    | BMD T value        | .511                        | .020    |
| BMI (kg/m²)         | -.291                       | <.001   | ABI                | .673                        | <.001   |
| Waist circumference (cm) | -.208             | .010    | Insulin (µmol/L)   | -.284                       | <.001   |
| Hip circumference (cm) | -.346                       | <.001   | FBG (mmol/L)       | -.177                       | .025    |
| Waist-to-hip ratio  | -.170                       | .032    | IRI                | -.250                       | .003    |
| CRP                 | -.231                       | .005    | Chemerin           | -.527                       | <.001   |
| BNP                 | -.333                       | <.001   | ba-PWV             | -.554                       | <.001   |
| LDL-C               | -.209                       | .010    |                    |                             |         |

**Abbreviations:** ABI, ankle-brachial index; BMD T value, bone mineral density T value; BMI, body mass index; BNP, brain natriuretic peptide; CRP, C-reactive protein; DBP, diastolic blood pressure; FBG, fasting blood glucose; HDL-C, high-density lipoprotein cholesterol; IRI, insulin resistance index; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure.
in patients with T2DM, which should be considered for better prediction of atherosclerosis in T2DM patients. Thus, our data provide more support for utilizing chemerin and adiponectin levels as potential markers for vascular stiffness, together with ABI levels to better predict the early stage of atherosclerosis, and even for cardiovascular diseases.

In summary, chemerin and adiponectin levels in plasma are suggested as independent predictors for vascular stiffness, which promotes the development of subclinical atherosclerosis, and may be applied for the risk assessment of macrovascular diseases in clinical settings.

ACKNOWLEDGEMENTS

This study was supported by the National Natural Science Foundation of China (No. 81501212, No. 81370931) and the Hunan Province Special Health Research Projects (A2015-04).

CONFLICTS OF INTEREST

Nothing to disclose.

ORCID

Huahua Li https://orcid.org/0000-0002-5613-7677

REFERENCES

1. Sommer G, Kralisch S, Stangl V, et al. Secretory products from human adipocytes stimulate proinflammatory cytokine secretion from human endothelial cells. J Cell Biochem. 2009;106:729-737.
2. Kirkman MS, McCarren M, Shah J, Duckworth W, Abaira C, Grp VS. The association between metabolic control and prevalent macrovascular disease in type 2 diabetes: the VA Cooperative Study in diabetes. J Diabetes Complicat. 2006;20:75-80.
3. Oh KJ, Lee DS, Kim WK, Han BS, Lee SC, Bae KH. Metabolic adaptation in obesity and type II diabetes: myokines, adipokines and hepatokines. Int J Mol Sci. 2016;18:8.
4. Fulop P, Harangi M, Seres I, Paragh G. Paraoxonase-1 and adipokines: potential links between obesity and atherosclerosis. Chem-Biol Interact. 2016;259:388-393.
5. Andersson DP, Laurencikiene J, Acosta JR, Ryden M, Arner P. Circulating and adipose levels of adipokines associated with insulin sensitivity in nonobese subjects with type 2 diabetes. J Clin Endocr Metab. 2016;101:3765-3771.
6. Gelsinger C, Tschoner A, Kaser S, Ebenbichler CF. Adipokine update - new molecules, new functions [in German]. Wien Med Wochenschr. 2010;160:377-390.
7. Masugata H, Senda S, Goda F, et al. A new index of “cardiac age” derived from echocardiography: influence of hypertension and comparison with pulse wave velocity. Hypertens Res. 2008;31:1573-1581.
8. Tomiyama H, Aral T, Koj Y, et al. The relationship between high-sensitive C-reactive protein and pulse wave velocity in healthy Japanese men. Atherosclerosis. 2004;174:373-377.
9. Aydin K, Canpolat U, Akin S, et al. Chemerin is not associated with subclinical atherosclerosis markers in prediabetes and diabetes. Anatol J Cardiol. 2016;16:749-755.
10. Lachine NA, Elnekiedy AA, Megallaa MH, et al. Serum chemerin and high-sensitivity C reactive protein as markers of subclinical atherosclerosis in Egyptian patients with type 2 diabetes. Ther Adv Endocrinol. 2016;7:47-56.
11. Aguilera E, Serra-Planas E, Granada ML, et al. Relationship of YKL-40 and adiponectin and subclinical atherosclerosis in asymptomatic patients with type 1 diabetes mellitus from a European Mediterranean population. Cardiovas Diabetol. 2015;14:121.
12. Sheu Y, Amati F, Schwartz AV, et al. Vertebral bone marrow fat, bone mineral density and diabetes: The Osteoporotic Fractures in Men (MrOS) study. Bone. 2017;97:299-305.
13. Akhtar B, Siddique S, Khan RA, Zulfiqar S. Detection of atherosclerosis by ankle brachial index: evaluation of palpatory method versus ultrasound Doppler technique. J Ayub Med Coll Abbottabad. 2009;21:11-16.
14. Jacob C. Statistical Power Analysis for the Behavioral Sciences. 2nd edn. Hillsdale, MI: Lawrence Erlbaum Associates; 1988.
15. Roh SG, Song SH, Choi KC, et al. Chemerin - a new adipokine that modulates adipogenesis via its own receptor. Biochem Biophys Res Commun. 2007;362:1013-1018.
16. Yan Q, Zhang YF, Hong J, et al. The association of serum chemerin level with risk of coronary artery disease in Chinese adults. Endocrine. 2012;41:281-288.
17. Kanter JE, Bornfeldt KE. Inflammation and diabetes-accelerated atherosclerosis: myeloid cell mediators. Trends Endocr Met. 2013;24:137-144.
18. McEniery CM, Yasin, Maki-Petaja KM, et al. The impact of cardiovascular risk factors on aortic stiffness and wave reflections depends on age: the Anglo-Cardiff Collaborative Trial (ACCT III). Hypertension. 2010;56:591-597.
19. Paini A, Boutouyrie P, Calvet D, Tropeano AI, Laloux B, Laurent S. Carotid and aortic stiffness: determinants of discrepancies. Hypertension. 2006;47:371-376.
20. Park JS, Nam JS, Cho MH, et al. Insulin resistance independently influences arterial stiffness in normoglycemic normotensive postmenopausal women. Menopause. 2010;17:779-784.
21. Li CH, Wu JS, Yang YC, Shih CC, Lu FH, Chang CJ. Increased arterial stiffness in subjects with impaired glucose tolerance and newly diagnosed diabetes but not isolated impaired fasting glucose. J Clin Endocrinol Metab. 2012;97:E658-E662.

TABLE 6  Multiple regression analysis of chemerin with ba-PWV levels

| Model | Unstandardized coefficient | Standardized coefficient |
|-------|-----------------------------|--------------------------|
|       | partial regression coefficient (B) | SE | β | t | P |
| Constant | 56.948 | 5.490 | 9.328 | 6.445 | <.001 |
| ba-PWV | 0.022 | 0.003 | 0.545 | 6.445 | <.001 |
| BMD T value | −4.484 | 1.158 | −0.327 | 3.553 | .001 |

Abbreviations: ba-PWV, brachial-ankle pulse wave velocity; BMD T value, bone mineral density T value.
22. Steinberg HO, Tarshoby M, Monestel R, et al. Elevated circulating free fatty acid levels impair endothelium-dependent vasodilation. J Clin Invest. 1997;100:1230-1239.

23. Mahmud A, Feely J. Adiponectin and arterial stiffness. Am J Hypertens. 2005;18:1543-1548.

24. Park JS, Kang SA, Yoo JS, et al. Association between gamma-glutamyltransferase, adiponectin and arterial stiffness. J Atheroscler Thromb. 2012;19:90-97.

25. Windham BG, Griswold ME, Farasat SM, et al. Influence of leptin, adiponectin, and resistin on the association between abdominal adiposity and arterial stiffness. Am J Hypertens. 2010;23:501-507.

26. Maedeker JA, Stoka KV, Bhayani SA, et al. Hypertension and decreased aortic compliance due to reduced elastin amounts do not increase atherosclerotic plaque accumulation in Ldlr−/− mice. Atherosclerosis. 2016;249:22-29.

27. Stern JH, Rutkowski JM, Scherer PE. Adiponectin, leptin, and fatty acids in the maintenance of metabolic homeostasis through adipose tissue crosstalk. Cell Metab. 2016;23:770-784.

28. Harwood HJ. The adipocyte as an endocrine organ in the regulation of metabolic homeostasis. Neuropharmacology. 2012;63:57-75.

29. Arner P. The adipocyte in insulin resistance: key molecules and the impact of the thiazolidinediones. Trends Endocrin Met. 2003;14:137-145.

30. Fatima SS, Rehman R, Baig M, Khan TA. New roles of the multidimensional adipokine: Chemerin. Peptides. 2014;62:15-20.

31. McCarthy TC, Zuniga LA, Zabe BA, Butcher EC, Sinai CJ. The novel adipokine chemerin significantly increases cholesterol uptake in human macrophages. FASEB J. 2008;22:948.

32. Li XM, Ji H, Li CJ, Wang PH, Yu P, Yu DM. Chemerin expression in Chinese pregnant women with and without gestational diabetes mellitus. Ann Endocrinol-Paris. 2015;76:19-24.

33. Ouchi N, Kihara S, Arita Y, et al. Novel modulator for endothelial adhesion molecules - adipocyte-derived plasma protein adiponectin. Circulation. 1999;100:2473-2476.

34. Yokota T, Oritani K, Takahashi I, et al. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood. 2000;96:1723-1732.

35. Hotta K, Funahashi T, Bodkin NL, et al. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes. 2001;50:1126-1133.

36. Lu B, Zhao M, Jiang WM, et al. Independent association of circulating level of chemerin with functional and early morphological vascular changes in newly diagnosed type 2 diabetic patients. Medicine. 2015;94:e1990.

37. Li T, Wu XJ, Chen XM, Wang SB, Liu KD, Xing YQ. Ankle-brachial index and brachial-ankle pulse wave velocity are risk factors for ischemic stroke in patients with type 2 diabetes. Neural Regen Res. 2017;12:1853-1859.

How to cite this article: Li H, Zhan J, Liao B, Wang Y, Liu Y. Plasma levels of adiponectin and chemerin are associated with early stage of atherosclerosis in older adults with type 2 diabetes mellitus. Aging Med. 2019;2:198-206. https://doi.org/10.1002/agm2.12087